Printer Friendly

Salugen to Present Research on Generational Associations of Reward Deficiency Syndrome at XVth World Congress on Psychiatric Genetics.

SAN DIEGO, Oct. 8 /PRNewswire/ -- Salugen, Inc., a personalized health and wellness company will present its research entitled: Generational Association Studies of Dopaminergic Genes (DRD1, DRD2, DAT1, & DBH) In Reward Deficiency Syndrome (RDS): A Paradigm Shift In Selecting Appropriate Phenotypes For Reward Dependence Behaviors at the XVth World Congress on Psychiatric Genetics October 7 - 11, 2007 in New York City, NY.

Dr. Kenneth Blum, Chief Scientific Officer of Salugen will discuss the generational association of genes associated with Reward Deficiency Syndrome (RDS). Numerous studies have revealed an association between certain dopaminergic gene polymorphisms and a number of reward dependent behaviors including addictive, compulsive and impulsive tendencies. These interrelated reward-dependent behaviors involving dopaminergic genes have been classified as RDS.

Additionally, he will present findings corresponding to multi-factorial phenotypes associated with the genes including ADHA, alcoholism, cocaine dependence, intravenous drug dependence, carbohydrate binging, smoking, hyperactivity, sex addiction, pathological violence, Tourette Syndrome, autism, and other personality disorders in an experimental group of 55 subjects derived from up to five generations of two independent multiple- affected families.

Salugen CEO Brian Meshkin states, "We are pleased to present Salugen's continued research on RDS. These findings aid us in furthering the clinical application of the research to assist those with a genetic predisposition to conditions associated with RDS."

Salugen currently markets DNA-customized nutritional solutions under three brands, GenoTrim(TM) for weight management (http://www.genotrim.com/), SpaGen(TM) for optimal health and wellness (http://www.spagen.com/) and Haveos(TM) for substance abuse attenuation.

About Salugen

Salugen, Inc., a leading personalized health and wellness company, engages in the discovery, development and commercialization of patent-protected genetic tests and companion DNA-customized therapeutics worldwide. With over 30 years of research conducted on the genetic causes and pharmacology of many healthcare concerns, Salugen is a pioneer and leader in delivering personalized medicine. Currently, the Company commercializes nutrigenomic technologies where genetic analysis guides the formulation and delivery of nutritional solutions that are customized to the individual. The company has headquarters in San Diego, CA, with its high-complexity CLIA-certified laboratory services in Los Angeles, CA. For additional information about the company, please visit http://www.salugen.com/.

CONTACT: Salugen, Inc., +1-858-535-4825, or fax, +1-858-535-4890

Web site: http://www.salugen.com/
COPYRIGHT 2007 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 8, 2007
Words:368
Previous Article:Viridian Named 'High-Rise Project of the Year'.
Next Article:Naval CNO Visits Philadelphia's Navy League.


Related Articles
GENETICS INSTITUTE'S rhFACTOR IX ADVANCES TO GLOBAL PHASE 3 CLINICAL TRIALS
Insulin Resistance Syndrome (IRS): A Fatal Disorder - Experts Call for Action.
Salugen Announces the U.S. Launch of GenoTrim - a DNA Customized Nutritional Solution for Weight Management.
Salugen's Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual...
15th World Congress of Psychiatry.
22nd ECNP Congress 2009: The Future of Schizophrenia.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters